1.
Zirwas M, Draelos Z, Dubois J, Kircik L, Moore A, Stein Gold L, Alonso-Llamazares J, Bukhalo M, Bruce S, Eads K, Green L, Guenthner S, Ferris L, Forman S, Kempers S, Lain E, Lynde C, Pariser D, Pariser D, Toth D, Yamauchi paul, Burnett P, Berk D. A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis. J of Skin [Internet]. 2021Nov.5 [cited 2022Dec.1];5(6):s94. Available from: https://www.jofskin.org/index.php/skin/article/view/1445